Clinical scenario: GBS| IVIG | Recurrent weakness | Diagnosis
A 12-year-old boy develops progressive ascending weakness over 6 days following an episode of acute gastroenteritis. Examination reveals symmetrical flaccid quadriparesis, generalized areflexia, and bilateral lower motor neuron facial weakness. CSF shows albuminocytologic dissociation, and nerve conduction studies are consistent with acute inflammatory demyelinating polyradiculoneuropathy (AIDP).
He is treated with IVIG (2 g/kg) and improves steadily. Three weeks after the onset of illness, he develops recurrent weakness with worsening gait, reduced upper limb power, and recurrent facial weakness. There is no fever, electrolyte abnormality, or evidence of a new infection.
A second course of IVIG is administered, and he again improves. Four weeks later (7 weeks from symptom onset), he experiences another episode of worsening weakness requiring readmission.
Which of the following is the most likely diagnosis?
A. Acute-onset chronic inflammatory demyelinating polyradiculoneuropathy (A-CIDP)
B. Guillain-Barré syndrome with treatment-related fluctuation (TRF)
C. Miller Fisher syndrome
D. Recurrent Guillain-Barré syndrome
E. Acute motor axonal neuropathy (AMAN)
Correct answer & Explanation:
Correct Answer: A. Acute-onset chronic inflammatory demyelinating polyradiculoneuropathy (A-CIDP)
Explanation
The distinction between GBS with treatment-related fluctuation (TRF) and acute-onset CIDP (A-CIDP) is based mainly on the time course.
This child initially had classical GBS and improved after IVIG. However:
- He deteriorated again at 7 weeks from symptom onset.
- Deterioration beyond 8 weeks from onset or three or more treatment-related deteriorations strongly suggests A-CIDP rather than GBS with TRF.
Patients with A-CIDP require long-term immunomodulatory therapy (e.g., repeated IVIG, corticosteroids, or other steroid-sparing agents), unlike GBS, which is usually monophasic.
Why the other options are incorrect
- A. Acute-onset CIDP – Correct. Recurrent deterioration extending beyond the expected monophasic course of GBS suggests A-CIDP.
- B. Treatment-related fluctuation – Incorrect. TRF usually occurs within the first 8 weeks after onset and is generally limited to one or two deteriorations after initial improvement.
- C. Miller Fisher syndrome – Incorrect. Characterized by ophthalmoplegia, ataxia, and areflexia.
- D. Recurrent GBS – Incorrect. Episodes are separated by months or years, not weeks.
- E. AMAN – Incorrect. This is an electrophysiological subtype of GBS and does not explain the relapsing clinical course.
Learning Point
A patient who initially appears to have GBS but develops repeated relapses or continued deterioration beyond the expected monophasic course (especially beyond 8 weeks or after ≥3 deteriorations) should be evaluated for acute-onset CIDP, as management differs significantly.
